Novo Nordisk's Danish Double Whammy: A Legal Hurdle and a Missed Pill Target

Novo Nordisk shares fall 15% in 7 days after oral Wegovy revenue misses forecasts, while legal and competitive pressures mount.

Investors who bought Novo Nordisk at January's peak of 54.86 euros have watched nearly a third of their stake evaporate. The latest blow came Tuesday, when the Danish pharma giant shed more than 6 percent of its value in a single session, closing at 38.39 euros on the Frankfurt exchange. Over seven trading days, the cumulative decline has reached roughly 15 percent.

The sell-off unfolded despite what should have been reassuring news. Novo Nordisk narrowed its 2026 guidance, now projecting a 0 to 6 percent decline in adjusted revenue and operating profit—an improvement over the previous forecast of a 4 to 12 percent drop. Management also confirmed the ongoing share buyback program, which has already repurchased 7.5 billion Danish kroner worth of B-shares at an average price of 278.35 kroner, with up to 15 billion kroner authorized in total.

The Pill That Missed by a Hair

The market's disappointment traces to a single product line. Oral Wegovy generated 3.22 billion kroner in second-quarter revenue, narrowly missing analyst consensus of 3.27 billion. That 50-million-kroner gap proved decisive. A Mizuho Securities analyst pointed to the lack of upside in the pill's performance relative to model expectations as the primary driver of selling pressure.

The context makes the miss sting more. Second-quarter revenue rose 2 percent year-over-year to 78.488 billion kroner, but that figure masks a 19 percent sequential decline from Q1. A one-off benefit in the prior-year quarter—rebate reimbursements tied to the US 340B program—distorted the comparison. Adjusted for such effects, growth came in at 7 percent.

CEO Mike Doustdar noted that oral Wegovy has surpassed 5 million prescriptions since its January launch. Yet the competitive landscape has shifted dramatically. Eli Lilly received FDA approval for its own oral GLP-1 pill, Foundayo, in April and moved quickly to market, intensifying the rivalry beyond injectables into the tablet segment.

From Laboratory Setback to Courtroom

The legal dimension adds a layer of complexity that pure earnings numbers cannot capture. A US federal judge has allowed portions of a shareholder lawsuit to proceed to discovery. Investors have plausibly alleged that Novo Nordisk's statements about CagriSema's tolerability and the design of its late-stage trial may have been misleading.

The case traces back to February, when CagriSema patients lost an average of 20.2 percent of their body weight—short of the 23.6 percent achieved by Eli Lilly's Tirzepatid. The result meant CagriSema failed its primary non-inferiority endpoint against the rival treatment. Doustdar has pushed back on that interpretation, telling CNBC the market overreacted to the data and that further studies would provide a fuller picture.

The court ruling does not establish guilt or determine that securities fraud occurred. It does, however, open the door to months of discovery and headline risk, potentially extending well into 2027. A company spokesperson dismissed the allegations as unfounded and pledged a vigorous defense.

Technicals Offer Little Comfort

The chart paints a picture of persistent pressure. The stock trades 6.25 percent below its 50-day moving average of 40.95 euros. The RSI sits at 33.5, firmly in oversold territory, yet no reversal signal has emerged. Annualized volatility has climbed to 38.33 percent, reflecting heightened nervousness in the trading pattern.

The March 52-week low of 30.25 euros remains a distant floor, but the velocity of the recent decline illustrates how sensitive the market has become to any deviation from the lofty expectations surrounding the GLP-1 franchise. The company continues buying back shares at levels above the current market price—44,249,480 B-shares held, representing 1.0 percent of share capital—yet that support has done little to stem the tide.

What makes this moment notable is not the single-day drop itself. Pharmaceutical stocks routinely move 5 percent in a session. The convergence of a clinical setback, intensifying competition from Lilly, and now a legal proceeding that could keep the CagriSema question alive for years creates a weight that no single earnings beat could offset. Novo Nordisk entered 2025 hoping to demonstrate that its obesity franchise could withstand competitive pressure. Instead, it finds itself defending its pipeline, its disclosures, and its valuation all at once.